Angiokeratoma of Mibelli is a genetic skin condition with small, dark-red to blue bumps that feel rough. These spots often appear on fingers, toes, hands, or feet and may bleed with minor injury. It usually begins in childhood or adolescence and tends to be long-lasting. People with angiokeratoma of Mibelli are otherwise healthy, and life expectancy is normal. Treatment focuses on comfort and appearance, with options like laser therapy or freezing when spots are bothersome or bleed.
Overview
Angiokeratoma of mibelliSymptoms
Early symptoms of Angiokeratoma of mibelli include small, rough, dark red to blue-black bumps on fingers and toes, often clustered. They’re usually painless but may itch, feel tender, or bleed after minor knocks, especially in cold weather.
Outlook and prognosis
Most people with angiokeratoma of Mibelli live well, though the spots can persist and slowly increase over time. They’re benign, but may bleed, itch, or cause cosmetic concerns. Treatments can reduce or remove lesions, and recurrence varies by person.
Causes and risk factors
Angiokeratoma of Mibelli often stems from fragile surface blood vessels and increased local pressure, triggered by cold exposure, chilblains, or repeated minor trauma. Risks rise during puberty, with family tendency, Raynaud-type circulation, smoking, and conditions causing poor peripheral circulation.
Genetic influences
Genetics play a modest role in Angiokeratoma of Mibelli. Some families show autosomal dominant patterns, suggesting inherited susceptibility, but many cases appear sporadic. Variants affecting small blood vessel structure or skin response may increase risk, with variable expressivity.
Diagnosis
Diagnosis of angiokeratoma of Mibelli is usually clinical, supported by dermoscopy and sometimes a skin biopsy. Doctors also exclude look-alikes (e.g., melanoma, warts) and assess for Fabry disease if lesions are widespread.
Treatment and drugs
Treatment for angiokeratoma of Mibelli focuses on comfort, appearance, and preventing bleeding. Options include gentle skin care, treating itch or pain, and removing spots with laser, electrosurgery, cryotherapy, or surgical excision. Your dermatologist tailors choices to symptom severity and location.
Symptoms
Angiokeratoma of mibelli causes small, dark, rough skin bumps that often show up on the fingers, toes, hands, or feet. These spots are harmless but can snag on clothing or bleed when rubbed, which can be frustrating in daily life. Symptoms vary from person to person and can change over time. Many people first notice them during the teen years, and they may look more prominent in cold weather.
Early symptoms of Angiokeratoma of mibelli often show up as tiny, rough, red to blue-black bumps on fingers or toes. They may look like warts or old scabs. The color can deepen slowly.
The top can feel hard, scaly, or wart-like. This thickening can make the bumps catch on socks or gloves. Moisturizers may soften skin but won't flatten the bumps completely.
Spots cluster on the backs or sides of the fingers and toes, and sometimes on the hands or feet. They can appear on both sides in similar areas. Spots on the face or trunk are uncommon.
Light rubbing, shaving, or scratching can make a bump bleed like a pinprick. The bleeding is usually brief but can leave a small crust. Covering with a small bandage helps until it clots.
How people usually first notice Angiokeratoma of mibelli?
Many first notice small, dark red to blue-black bumps on the backs of fingers, toes, or knuckles that slowly appear in the teen years, especially in cold weather. These spots can feel rough or warty, may cluster, and sometimes bleed if rubbed or injured, prompting a visit to a clinician. Doctors often recognize these as angiokeratoma of Mibelli during a skin exam, confirming the first signs of angiokeratoma of Mibelli by their typical location, color, and thickened surface.
Types of Angiokeratoma of mibelli
Angiokeratoma of Mibelli is a genetic/congenital skin condition that shows up as clusters of small, dark, rough bumps, often on the backs of fingers, toes, elbows, or knees. There aren’t multiple gene-defined variants with different enzyme defects, but clinicians do recognize a few clinical patterns based on where and how the spots appear and whether they coexist with other angiokeratoma types. People may notice different sets of symptoms depending on their situation. When reading about types of Angiokeratoma of Mibelli, you’ll mainly see clinical variants described by location, age at onset, and context rather than distinct molecular subtypes.
Classic acral pattern
Lesions cluster symmetrically on fingers and toes, sometimes over knuckles. They may thicken and darken with cold weather or minor trauma, leading to occasional bleeding. Early symptoms of Angiokeratoma of Mibelli often include small, rough, red‑to‑blue spots that slowly turn darker.
Periarticular variant
Bumps form around small joints, like knuckles or toe joints, and can feel rough or warty. Friction from gloves, shoes, or sports equipment may make them more noticeable. Bleeding can occur if the surface cracks.
Childhood‑onset form
Spots begin in late childhood or early teens, often during puberty. They tend to grow in number and size over time, then stabilize in adulthood. Not everyone will experience every type.
Coexisting types context
Some people also have other angiokeratoma patterns (like on the scrotum or vulva), but the acral lesions behave like Mibelli. Symptoms include color change from red to blue‑black and a firm, rough surface. Loved ones may recognize certain types sooner than the person experiencing them.
Cold‑sensitive pattern
Lesions feel more raised and look darker in cold exposure, with occasional itch or tenderness. Warming and protective clothing may lessen flares. Share with your healthcare provider whether symptoms worsen with cold or friction.
What genetics can tell you about symptoms
Certain variants in the X-linked GLA gene can change how skin’s tiny blood vessels behave, causing dark red to purple, rough, wart-like spots on fingers, toes, elbows, or knees during adolescence or cold exposure. Some families show earlier onset and more numerous lesions, reflecting inherited risk.
Causes and risk factors
Angiokeratoma of Mibelli tends to form when tiny blood vessels in the skin widen and the top layer thickens.
Cold exposure, repeated friction, and past cold injuries like frostbite or chilblains can raise the chance.
Some risks are modifiable (things you can change), others are non-modifiable (things you can’t).
A family tendency may play a role, and it often starts around puberty.
If early symptoms of angiokeratoma of Mibelli appear after cold or rubbing, those triggers may be part of your risk.
Environmental and biological risk factors
Angiokeratoma of Mibelli often appears on the fingers and toes and tends to start in adolescence. In everyday life, the spots can swell or bleed if bumped, especially in cold weather. Two people with the same exposure can react very differently—biology shapes the response. Cold snaps and surface irritation often come right before early symptoms of Angiokeratoma of Mibelli, so timing with winter months is common.
Low temperatures tighten surface blood vessels and cause quick rewarming swings. For Angiokeratoma of Mibelli, those shifts can strain tiny vessels in fingers and toes. Flare-ups are often noted in winter.
Repeated cold-induced skin inflammation can injure small vessels. This damage can set the stage for Angiokeratoma of Mibelli on acral skin.
Ongoing rubbing or minor knocks can irritate superficial vessels. In Angiokeratoma of Mibelli, micro-injury may promote vessel widening and thicker surface skin.
If your hands or feet blanch, turn blue, or ache in the cold, vessels are reacting strongly. That reactivity may raise risk for Angiokeratoma of Mibelli on exposed areas.
Genetic risk factors
If you or a relative has small, rough, dark-red skin spots on the fingers or toes, it’s natural to wonder whether others in the family could develop them too. For Angiokeratoma of mibelli, most cases occur on their own without a known inherited cause, but family patterns have been reported in a few households. Risk is not destiny—it varies widely between individuals. Understanding the genetic background can help you spot early symptoms of Angiokeratoma of mibelli and decide whether to ask a clinician about evaluation.
Sporadic cases: Most people with Angiokeratoma of mibelli have no family history and no identifiable inherited cause. In these cases, the spots develop without a single gene driving them.
Familial tendency: Rare reports show several relatives with similar lesions, suggesting a modest inherited predisposition. Not everyone in an affected family develops them, and severity can differ.
No single gene: A specific causative gene for Angiokeratoma of mibelli has not been confirmed. Because of this, routine genetic testing is not usually helpful.
Fabry disease distinction: Widespread angiokeratomas linked to GLA gene changes occur in Fabry disease, a different condition from Angiokeratoma of mibelli. Testing for Fabry is considered when lesions are diffuse and other systemic signs are present.
Lifestyle risk factors
Angiokeratoma of Mibelli often appears on fingers and toes and can be irritated by habits that raise local pressure or cause repeated skin trauma. While not caused by lifestyle alone, certain choices can make lesions more numerous, larger, or more likely to bleed. Understanding lifestyle risk factors for Angiokeratoma of mibelli can help you reduce irritation and manage symptoms day to day.
Ongoing rubbing from sports equipment, tools, or tight footwear/gloves can micro-injure skin and dilated vessels. This can trigger new angiokeratomas or make existing ones thicker and prone to bleeding.
Constrictive socks, sleeves, or braces increase local venous pressure and shear on acral skin. Higher pressure can engorge lesions and raise the chance of bleeding with minor bumps.
Long periods on your feet promote venous pooling in the legs and feet. Pooling can make acral angiokeratomas more prominent and easier to traumatize during daily activities.
Breath-holding with heavy lifting spikes venous pressure in the extremities. Sudden pressure surges can transiently enlarge lesions and increase bleeding risk if they are nicked.
Risk prevention
Angiokeratoma of Mibelli often shows up on fingers and toes, especially with cold and friction. Prevention is about lowering risk, not eliminating it completely. Keeping the skin warm and protected, and supporting healthy circulation, can limit new spots and reduce bleeding. If you notice early symptoms of angiokeratoma of Mibelli—tiny dark-red bumps that thicken over time—ask a clinician about ways to prevent irritation and complications.
Wear gloves, thick socks, and insulated shoes to protect fingers and toes from cold. Avoid sudden temperature drops and staying in wet gloves or socks.
Use fragrance-free moisturizers daily to keep skin supple. Short, lukewarm showers and mild cleansers help prevent dryness and cracking that can irritate lesions.
Choose cushioned socks and well-fitted shoes, and wear gloves for manual work or sports. Avoid picking or scratching bumps to lower the chance of bleeding.
Take regular movement breaks, wiggle fingers and toes, and elevate feet when resting. Avoid nicotine, which narrows blood vessels and can worsen symptoms.
Transmission
Angiokeratoma of Mibelli is not contagious, so it cannot be “caught,” passed on, or sexually transmitted. If you’re wondering how Angiokeratoma of Mibelli spreads, it doesn’t transfer between people through touch, shared towels, or the air. Spots may slowly increase in number in the same area over time, often triggered by cold exposure or friction, but that’s a local skin change rather than an infection. Rarely, there can be a family tendency to develop these lesions, yet there’s no clear single inheritance pattern and many cases occur without a family history.
When to test your genes
Consider genetic testing if you or close relatives developed angiokeratoma of Mibelli at a young age, have many or widespread lesions, or there’s a family history suggesting an inherited pattern. Testing is also reasonable when lesions appear alongside cold sensitivity, numbness, or other skin findings that suggest a syndromic cause. Results can guide monitoring, dermatologist referrals, and family planning.
Diagnosis
Small, rough, dark-red to purple bumps on the fingers or toes can catch your attention, especially if they snag on clothing or bleed after minor friction. For many, the first step comes when everyday activities start feeling harder, like pulling on gloves or typing when a spot is tender. Doctors usually begin with a careful skin exam and then add simple tools to confirm the cause. Below is how the diagnosis of Angiokeratoma of mibelli is typically made in routine care.
A clinician looks closely at the size, color, texture, and location of the bumps, often on the backs or sides of fingers and toes. They ask about bleeding, pain, cold sensitivity, and when the spots first appeared. This helps distinguish them from warts, moles, or other vascular growths.
A handheld skin scope lets the doctor see patterns of dark-red to blue “lagoons” under a thin, rough surface. These features are characteristic of angiokeratomas and reduce confusion with melanoma or other skin cancers. It’s quick, painless, and done in the office.
If the appearance is atypical or changing, a tiny sample is taken after numbing the area. Lab review confirms enlarged surface blood vessels with a thickened top layer, which supports Angiokeratoma of Mibelli. Biopsy also rules out skin cancer when there’s uncertainty.
The number and distribution of spots help guide diagnosis. Clustered lesions on acral areas point to Angiokeratoma of Mibelli, while widespread lesions on the trunk or groin suggest a different type. From here, the focus shifts to confirming or ruling out possible causes.
Stages of Angiokeratoma of mibelli
Angiokeratoma of mibelli does not have defined progression stages. The spots can appear over time and sometimes increase in number, but they don’t follow a predictable step-by-step pattern like some conditions do. Doctors usually start with a conversation about where and when the spots appear, any bleeding, and what seems to trigger them, followed by a skin exam and dermoscopy. Early symptoms of Angiokeratoma of mibelli include small, dark red to blue bumps on the fingers or toes that may bleed if rubbed; diagnosis is often confirmed by dermoscopy, and sometimes a small skin biopsy is done to rule out look-alike conditions.
Outlook and prognosis
Living with Angiokeratoma of Mibelli often means dealing with small, dark-red to blue skin spots that can thicken over time and bleed with minor bumps or shaving. Many people ask, “What does this mean for my future?”, and the short answer is that this condition is considered benign and doesn’t shorten life expectancy. The main day-to-day impact comes from skin irritation, bleeding, and cosmetic concerns, especially on fingers, toes, hands, or feet where friction is common.
Prognosis refers to how a condition tends to change or stabilize over time. For most people with Angiokeratoma of Mibelli, lesions develop gradually in adolescence and can slowly increase in number or size before leveling off. They don’t turn into skin cancer, but occasional bleeding and crusting can happen, particularly in cold weather or with frequent rubbing. Early care can make a real difference, since simple steps—protective gloves in winter, gentle skin care, and avoiding trauma—reduce bleeding and discomfort.
Treatment is usually for symptoms or appearance. Options like laser, electrosurgery, or freezing can remove or shrink lesions, though new spots may appear later and touch-up treatment may be needed. Mortality is not increased with Angiokeratoma of Mibelli, and serious complications are rare. Talk with your doctor about what your personal outlook might look like, including when to treat, how to manage early symptoms of Angiokeratoma of Mibelli, and what to watch for if spots change or bleed more often.
Long-term effects
Angiokeratoma of Mibelli usually follows a slow, steady course with spots that persist over years. Long-term effects vary widely, but most remain limited to the skin without affecting internal organs. Many people notice flares in colder months, occasional bleeding with friction, and cosmetic concerns that influence clothing or activity choices. Treatments can improve appearance or reduce bleeding, though spots may return over time.
Early symptoms of Angiokeratoma of Mibelli often appear in adolescence as small, dark-red to blue bumps on fingers, toes, or knees. These spots tend to persist and may slowly increase in number. Growth is usually gradual rather than sudden.
Lesions typically remain for years without turning cancerous. They may thicken and darken with time, but malignant change is not expected. Many remain localized to hands, feet, elbows, or knees.
Spots can bleed with minor trauma, like rubbing against shoes or during sports. Bleeding is usually brief but can be messy or startling. Repeated friction may lead to crusting or irritation.
Cold weather can make spots swell, darken, or feel tender. Some people notice more bleeding or discomfort in winter. Warming the area often eases symptoms.
How is it to live with Angiokeratoma of mibelli?
Daily life with angiokeratoma of Mibelli often means managing small, dark-red to blue skin spots—usually on fingers, toes, hands, or feet—that can thicken over time and sometimes itch, crack, or bleed with friction or cold weather. Many living with it plan around triggers like cold exposure, tight shoes, or manual work, using gentle skin care, moisturizers, and protective gloves or socks to reduce irritation and bleeding. The condition is benign, but the visible lesions can draw questions or unwanted attention; sharing a simple explanation with friends, family, or coworkers can ease social discomfort and help others understand why you might avoid the cold or cover the areas. Dermatology visits for diagnosis, reassurance, or treatments such as laser can be part of routine care, and for many, that partnership keeps symptoms and worry in check.
Treatment and drugs
Angiokeratoma of Mibelli is usually treated to reduce bleeding, discomfort, or cosmetic concerns, and plans are tailored to how many spots you have, where they are, and whether they’re causing symptoms. Small, bothersome lesions can be removed in the clinic with methods that seal or destroy the tiny surface blood vessels, such as laser therapy (often pulsed dye or Nd:YAG), electrocautery, cryotherapy (freezing), or surgical shave removal; a doctor may numb the area first to keep you comfortable. Thick or repeatedly bleeding lesions may need a combination approach or repeat sessions, and petroleum jelly or antibiotic ointment is typically used during healing to lower infection risk and improve skin recovery. Alongside medical treatment, lifestyle choices play a role, like protecting skin from friction or cold to prevent cracking and bleeding, and using gentle skincare to avoid irritation. If you’re unsure, write down questions to bring to your next visit, especially about expected healing time, scarring risk, and which option fits your goals.
Non-drug treatment
Non-drug care focuses on protecting skin, easing irritation, and removing spots that bother you or bleed. Early symptoms of Angiokeratoma of mibelli can include tiny, rough, dark-red bumps on fingers or toes that snag on clothing. Non-drug treatments often lay the foundation by reducing triggers like cold and friction before considering in-office procedures. Your dermatologist can help tailor choices based on where the spots are and how much they affect daily life.
Wear warm gloves and thick socks in cold weather to reduce flare-ups. Choose soft, non‑abrasive fabrics and avoid tight seams that rub.
Use mild cleansers and plain, fragrance‑free moisturizers to soften rough spots. Pat skin dry instead of rubbing to avoid irritation.
If a bump bleeds, apply firm pressure with clean gauze for 10–15 minutes. Elevate the area and use a simple adhesive bandage once bleeding stops.
If Angiokeratoma of mibelli spots are small and not bothersome, monitoring may be all that’s needed. Your doctor may suggest periodic skin checks to track any changes.
Your genes may have an impact on how drugs work for you
Some medications used for angiokeratoma of Mibelli—like topical retinoids or procedures needing local anesthetics—can work differently depending on genes that affect skin sensitivity, healing, and drug metabolism. Genetic differences may change effectiveness or side‑effects, guiding dose or alternative choices.
Pharmacological treatments
Angiokeratoma of Mibelli often needs procedures like laser, but medicines can still help with scaling, irritation, and bleeding risk. Drugs that target symptoms directly are called symptomatic treatments. Early symptoms of Angiokeratoma of Mibelli, like rough, dark bumps that snag on clothing, may improve when the skin surface is softened.
Salicylic acid creams or gels (for example 5–20%) and urea lotions (10–40%) gently thin the thick outer layer. This can make bumps feel flatter and less likely to catch and bleed. Lactic acid lotions are another option in this group.
Tretinoin or adapalene can smooth the surface by speeding up skin turnover. Side effects, if they occur, can often be eased by using a pea-sized amount and moisturizing.
Compounded sirolimus (rapamycin) cream or gel may help lighten and shrink angiokeratomas over time. This is an off-label option used by some dermatology clinics, with most people noticing gradual change over weeks to months.
Aluminum chloride solution (often 20–35%) can be applied by a clinician to stop active bleeding from a lesion. It works quickly in the office and may cause brief stinging.
Genetic influences
When people ask about the genetic causes of angiokeratoma of Mibelli, the short answer is that most cases appear sporadic rather than clearly inherited. In some families, similar lesions show up across generations, which suggests a small inherited predisposition that can vary widely in how it shows. Family history is one of the strongest clues to a genetic influence. So far, no single gene has been confirmed as the cause of angiokeratoma of Mibelli, and routine genetic testing usually isn’t needed when the spots are limited and otherwise typical. Genes, if involved, may act like a dimmer switch that slightly weakens tiny vessel walls, while triggers such as cold exposure, friction, or hormonal changes around puberty make the spots more noticeable. If angiokeratomas are widespread or come with other features like burning nerve pain, heat intolerance, or kidney problems, doctors may consider evaluating for other inherited conditions such as Fabry disease, which is genetically driven but distinct from angiokeratoma of Mibelli.
Is Angiokeratoma of mibelli genetic?
Genetics play a modest role in Angiokeratoma of Mibelli. Some families show autosomal dominant patterns, suggesting inherited susceptibility, but many cases appear sporadic. Variants affecting small blood vessel structure or skin response may increase risk, with variable expressivity.
Pharmacogenetics—how genetics influence drug effects
Most care for Angiokeratoma of Mibelli relies on in-office procedures rather than long-term tablets or creams, so there aren’t specific medications for Angiokeratoma of Mibelli or gene tests that dictate drug choice. When medicines are used around treatment—such as codeine or tramadol for short-term pain—differences in drug‑processing genes can affect how well they work or the chance of side effects, so your clinician may choose alternatives or adjust dosing. Anti‑inflammatory pain relievers like ibuprofen or naproxen may also be used after procedures, and gene differences can influence how quickly you clear these drugs, though routine pharmacogenetic testing isn’t usually necessary. Skin tone and natural pigment, which are partly genetic, also guide laser settings and device choice because deeper skin tones carry a higher risk of temporary light or dark marks after treatment. Not every difference in response is genetic, but your other health conditions, the size and depth of the lesions, and medicines you already take play a major role in planning Angiokeratoma of Mibelli treatment. It’s also different from the widespread angiokeratomas seen in Fabry disease—a genetic, systemic condition—so most people with Angiokeratoma of Mibelli do not need gene‑guided drugs. If you’ve had unusual reactions to pain medicines in the past, tell your dermatologist or surgeon so they can prepare a safer, more comfortable plan.
Interactions with other conditions
Cold-sensitive circulation problems can make Angiokeratoma of Mibelli act up, especially on fingers and toes in winter. Day-to-day, it can feel like one health issue amplifies the other. People with Raynaud’s or a history of chilblains may notice the spots darken, swell, or bleed more when their hands or feet get cold or damp. Angiokeratoma of Mibelli is not usually linked to internal organ disease, but if many dark spots appear widely beyond the hands and feet—along with features like burning pain in the hands/feet or less sweating than usual—doctors may check for Fabry disease, since those signs are not typical of early symptoms of Angiokeratoma of Mibelli.
Blood-thinning medicines and bleeding disorders can increase the chance that these bumps ooze after minor bumps or scratching, and irritated skin conditions like eczema can make them look inflamed and harder to tell apart from other rashes. If you also live with diabetes or poor circulation in the legs, healing after biopsy or laser treatment for Angiokeratoma of Mibelli may be slower, so your care team may plan extra wound care and follow-up.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described small, rough, dark spots on fingers and toes that bled easily in cold weather, long before there was a name for them. Families in colder regions sometimes remembered a parent or grandparent with similar speckled patches on knuckles that hardened over winters and softened in warmer months. Community stories often described the condition as harmless but bothersome, especially when the spots cracked after chores or outdoor work.
First described in the medical literature as “angiokeratoma of Mibelli” in the late 1800s, these spots were noted to cluster on the backs of the hands, feet, knees, and elbows. Early doctors focused on what they could see and feel: tiny, red‑black bumps with a wart‑like surface that might ooze if scraped. Initially understood only through symptoms, later reports connected the dots between cold exposure, reduced blood flow at the skin’s surface, and the way the outer skin layer thickened over time.
Over time, descriptions became more precise. Observers noticed that angiokeratoma of Mibelli tended to start in childhood or the teen years, appeared more often in people with frequent cold exposure, and waxed and waned with the seasons. As medical science evolved, clinicians separated these spots from other look‑alike conditions, including common warts and other types of angiokeratomas that appear in different patterns or are linked to underlying disorders. This helped set angiokeratoma of Mibelli apart as a surface skin condition rather than a sign of internal disease.
With each decade, dermatologists refined how the condition is evaluated and treated. Magnified skin exams and small biopsies showed dilated surface blood vessels covered by a thickened top skin layer, a pattern that explains why the bumps look dark and feel rough. Treatments shifted from simple cautery to options like freezing, lasers, or gentle surgical removal when bleeding, pain, or cosmetic concerns affected daily life. Yet watchful waiting remained reasonable for many living with angiokeratoma of Mibelli when the spots were stable and symptom‑free.
In recent decades, awareness has grown that “angiokeratoma” is an umbrella term for several patterns, and not all carry the same implications. That historical sorting—what belongs to Mibelli and what does not—reassures many that these particular lesions are typically localized to the skin. Knowing the condition’s history can help explain why a careful exam matters: it guides choices between simple reassurance and treatment only when needed.